Last reviewed · How we verify
Standard approach
At a glance
| Generic name | Standard approach |
|---|---|
| Sponsor | Clinical Hospital Colentina |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Implementation Science to Enhance HIV Testing Services During Emergency Care in Kenya (NA)
- Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (PHASE2)
- Group-Based Exercise Intervention to Prevent Cognitive and Motor Decline (NA)
- Transcatheter Aortic Valve Replacement Versu Surgical Aortix Valve Replacement for Treating Elderly Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Prospective Randomized Study The VIVA Trial (NA)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Healing Tiny Minds: Rural Recovery Through Virtual and Lived Experience Care (NA)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard approach CI brief — competitive landscape report
- Standard approach updates RSS · CI watch RSS
- Clinical Hospital Colentina portfolio CI